These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 29247285)

  • 1. Antioxidant-Based Eutectics of Irbesartan: Viable Multicomponent Forms for the Management of Hypertension.
    Haneef J; Chadha R
    AAPS PharmSciTech; 2018 Apr; 19(3):1191-1204. PubMed ID: 29247285
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Drug-Drug Multicomponent Solid Forms: Cocrystal, Coamorphous and Eutectic of Three Poorly Soluble Antihypertensive Drugs Using Mechanochemical Approach.
    Haneef J; Chadha R
    AAPS PharmSciTech; 2017 Aug; 18(6):2279-2290. PubMed ID: 28101724
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Candesartan cilexetil loaded solid lipid nanoparticles for oral delivery: characterization, pharmacokinetic and pharmacodynamic evaluation.
    Dudhipala N; Veerabrahma K
    Drug Deliv; 2016; 23(2):395-404. PubMed ID: 24865287
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Multicomponent solid forms of felodipine: preparation, characterisation, physicochemical and in-vivo studies.
    Chadha R; Sharma M; Haneef J
    J Pharm Pharmacol; 2017 Mar; 69(3):254-264. PubMed ID: 28134976
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Quality by design approach for oral bioavailability enhancement of irbesartan by self-nanoemulsifying tablets.
    Patel J; Dhingani A; Garala K; Raval M; Sheth N
    Drug Deliv; 2014 Sep; 21(6):412-35. PubMed ID: 24215334
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Irbesartan for hypertension.
    Med Lett Drugs Ther; 1998 Jan; 40(1019):18-9. PubMed ID: 9465857
    [No Abstract]   [Full Text] [Related]  

  • 7. Influence of Single and Multi Dose Treatment of Glipizide on Pharmacokinetics and Pharmacodynamics of Irbesartan in Normal and Hypertensive Rats.
    Anusha A; Narendar D; Krishna Murthy B; Goverdhan P
    High Blood Press Cardiovasc Prev; 2017 Jun; 24(2):179-185. PubMed ID: 28386752
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A look through the new therapeutic window: irbesartan.
    Waeber B; Brunner HR
    J Hypertens Suppl; 1998 Sep; 16(7):S11-6. PubMed ID: 9855026
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Irbesartan treatment in hypertension.
    Brown MJ
    Hosp Med; 1998 Oct; 59(10):808-11. PubMed ID: 9850301
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Implication of Coformer Structural Diversity on Cocrystallization Outcomes of Telmisartan with Improved Biopharmaceutical Performance.
    Haneef J; Arora P; Chadha R
    AAPS PharmSciTech; 2019 Dec; 21(1):10. PubMed ID: 31802267
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Drug interactions with irbesartan.
    Marino MR; Vachharajani NN
    Clin Pharmacokinet; 2001; 40(8):605-14. PubMed ID: 11523726
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A comparative assessment of solubility advantage from glassy and crystalline forms of a water-insoluble drug.
    Chawla G; Bansal AK
    Eur J Pharm Sci; 2007 Sep; 32(1):45-57. PubMed ID: 17618092
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Irbesartan: a review of its use in hypertension and in the management of diabetic nephropathy.
    Croom KF; Curran MP; Goa KL; Perry CM
    Drugs; 2004; 64(9):999-1028. PubMed ID: 15101793
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Irbesartan. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic use in the management of hypertension.
    Gillis JC; Markham A
    Drugs; 1997 Dec; 54(6):885-902. PubMed ID: 9421695
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Is Failure of Cocrystallization Actually a Failure? Eutectic Formation in Cocrystal Screening of Hesperetin.
    Chadha K; Karan M; Chadha R; Bhalla Y; Vasisht K
    J Pharm Sci; 2017 Aug; 106(8):2026-2036. PubMed ID: 28456725
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Experimental and DFT characterization, antioxidant and anticancer activities of a Cu(II)-irbesartan complex: structure-antihypertensive activity relationships in Cu(II)-sartan complexes.
    Islas MS; Luengo A; Franca CA; Merino MG; Calleros L; Rodriguez-Puyol M; Lezama L; Ferrer EG; Williams PA
    J Biol Inorg Chem; 2016 Oct; 21(7):851-63. PubMed ID: 27507083
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Differences in pharmacology and their translation into differences in clinical efficacy--a comparison of the renin angiotensin blocking agents irbesartan and losartan.
    Bramlage P; Schindler C
    Expert Opin Pharmacother; 2010 Mar; 11(4):521-35. PubMed ID: 20030566
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Association of cigarette smoking with steady-state plasma concentration of irbesartan in male Chinese with hypertension.
    Zhang S; Liu P; Jiang S; Hong X; Xing H; Xu X
    Methods Find Exp Clin Pharmacol; 2005 Apr; 27(3):173-8. PubMed ID: 15834449
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Individual and joint association of alpha1A-adrenergic receptor Arg347Cys polymorphism and plasma irbesartan concentration with blood pressure therapeutic response in Chinese hypertensive subjects.
    Jiang S; Mao G; Zhang S; Hong X; Tang G; Li Z; Liu X; Zhang Y; Wang B; Xu X; Wang X
    Clin Pharmacol Ther; 2005 Sep; 78(3):239-48. PubMed ID: 16153395
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The value of irbesartan in the management of hypertension.
    Bramlage P; Durand-Zaleski I; Desai N; Pirk O; Hacker C
    Expert Opin Pharmacother; 2009 Aug; 10(11):1817-31. PubMed ID: 19601700
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.